In March 2008, Bayer HealthCare LLC, a wholly owned subsidiary of Bayer Corporation, was granted a subject patent by India’s Patent Office, pursuant to the Drugs and Cosmetics Act 1940 (DCA) and Drugs and Cosmetics Rules 1945 (DCR), for “sorafenib tosylate” (ST), commonly prescribed for treatment of advanced renal cancer. Bayer HealthCare LLC subsequently assigned its titles to the patented drug in India to Bayer Corporation (“Bayer”).